Rigel Pharmaceuticals | RIGL - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Agenus USD 35M 32M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Anika Therapeutics USD 41.02M 16.46M 2026-03
Arrowhead Research USD 201.64M 112.94M 2025-12
AstraZeneca USD 7.56B 1.85B 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Celldex Therapeutics USD 35.73M 6.86M 2026-03
Daiichi Sankyo JPY 542.16B 97.68B 2025-09
Eli Lilly USD 5.28B 1.99B 2026-03
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Heron Therapeutics USD 26.12M 2.53M 2026-03
Intrexon USD 9.34M 1.77M 2024-06
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
Ligand Pharmaceuticals USD 115.08M 59.85M 2026-03
MacroGenics USD 66.52M 9.3M 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Pfizer USD 1.7B 561M 2026-03
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Veracyte USD 263.14M 99.44M 2026-03